ScreenerHero

ALGAE Fermentalg SA

EPA · FR · Healthcare · Biotechnology · fermentalg.com
0.4670EUR+2.75%Mkt Cap: 60.81M $P/E: —

Fermentalg SA provides biosolutions based on aquatic micro-organisms in Europe, North America, Asia, and internationally. It offers DHA ORIGINS, a plant-based DHA oil; KALVEA PLUS, a nutritious algal protein concentrate …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap60.81M USD
Enterprise Value45.75M USD
Revenue (TTM)14.55M USD
Gross Profit2.49M USD
Net Income (TTM)-10.26M USD
Revenue/Share0.13 EUR
Last Price0.4670 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees64
CountryFR
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.36
PEG—
EV/EBITDA-4.65
EV/Revenue3.15
P/S4.07
P/B1.73
EPS (TTM)-0.09
EPS (Forward)-0.04
52W Range
0.400028% of range0.6400
52W High0.6400 EUR
52W Low0.4000 EUR
Profitability
Gross Margin17.12%
Oper. Margin-100.16%
EBITDA Margin-67.66%
Profit Margin-70.51%
ROE-37.48%
ROA-25.88%
Growth
Revenue Growth11.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.16M USD
CapEx (TTM)1.67M USD
FCF Margin-42.74%
FCF Yield-10.23%
Net Debt-1.70M USD
Net Debt/EBITDA0.17
Balance Sheet
Debt/Equity0.20
Current Ratio1.96
Quick Ratio1.82
Book Value/Sh0.26 EUR
Cash/Share0.07 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.6400 EUR
Upside (mean)+37.0%
Target Range0.6300 EUR – 0.6500 EUR
0.6300+37.0% to mean0.6500
# Analysts2
Ownership
Shares Out.119.79M
Float61.95M
Insiders15.63%
Institutions17.92%
Technical
SMA 500.4620 (+1.1%)
SMA 2000.4785 (-2.4%)
Beta1.04
S&P 52W Chg14.58%
Avg Vol (30d)68.74K
Avg Vol (10d)72.90K
Technical Indicators
RSI (14)48.9
MACD-0.0044
MACD Signal-0.0049
MACD Hist.+0.0005
BB Upper0.4710 EUR
BB Middle0.4545 EUR
BB Lower0.4380 EUR
BB Width7.26%
ATR (14)0.0136 EUR
Vol Ratio (20d)3.99x